Anixa Biosciences Adjusts Presentation Timing for the H.C. Wainwright Investment Conference

Anixa Biosciences Updates Presentation Time at H.C. Wainwright Conference

San Jose, California – Anixa Biosciences, Inc. (NASDAQ: ANIX), a pioneering biotechnology firm focused on cancer treatment and prevention, has announced a change regarding its upcoming presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event is set to take place from September 8 to September 10, 2025, in New York City. The time for Anixa's presentation has been adjusted to 10:30 AM ET on September 9, 2025.

Mike Catelani, serving as the President and Chief Financial Officer of Anixa, will lead the presentation and will also be available for one-on-one meetings with attendees throughout the conference.

The details for the presentation are as follows:

- Event: H.C. Wainwright 27th Annual Global Investment Conference
- Date: September 9, 2025
- Time: 10:30 AM ET
- Location: Kennedy I – 4th Floor, Lotte New York Palace Hotel
- Webcast: Presentation Link

Anixa Biosciences is known for its innovative approach to combating cancer. The company is currently engaged in several groundbreaking initiatives, including an ovarian cancer immunotherapy that is being developed in partnership with Moffitt Cancer Center. This program utilizes a novel type of CAR-T, referred to as chimeric endocrine receptor-T cell (CER-T) technology. This method uniquely allows the natural ligand of the FSHR receptor, FSH, to bind directly to the tumor cell's FSHR receptor, diverging from traditional antibody fragment therapies.

Additionally, Anixa’s extensive therapeutic portfolio also includes various cancer vaccines that are being developed in collaboration with the Cleveland Clinic. These vaccines aim to treat and prevent breast and ovarian cancer, alongside provisions for other challenging cancers like lung, colon, and prostate malignancies.

The vaccines leverage a technology focusing on immunizing against certain proteins that display a significant presence in specific cancer types. Notably, both the breast and ovarian cancer vaccines were pioneered at the Cleveland Clinic and their commercialization has been exclusively licensed to Anixa, which is set to share a portion of revenues with the Cleveland Clinic.

Anixa's strategic business model relies on partnerships with renowned research institutions throughout all development stages. This collaborative approach enables the company to continuously explore emerging technologies from complementary fields for further development and commercialization.

Investors and stakeholders are reminded to attend the presentation for valuable insights into the company's innovative cancer treatments and the latest developments in their pipeline.

To learn more about Anixa Biosciences and its contributions to the field of biotechnology and cancer therapy, visit the company's official website www.anixa.com and follow them on social media platforms including LinkedIn, Twitter, Facebook, and YouTube.

Forward-Looking Statements
Statements made in this press release that are not historical facts are categorized as 'forward-looking statements.' These statements express Anixa's current expectations regarding future events and results. Words such as 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will,' and similar expressions are typically indicative of forward-looking statements. Risks and uncertainties could cause actual results to differ materially from those projected.

For inquiries or additional information, please contact:
Mike Catelani, President, COO & CFO
Email: [email protected]
Phone: 408-708-9808